DHSC Pledges Plan to Halt Spiraling Cost of Clinical Negligence ‘This Autumn’

Why It Matters

Unchecked liability growth threatens NHS financial sustainability and patient compensation fairness, prompting urgent policy intervention.

Key Takeaways

• Clinical negligence costs rose to $4.5 bn in 2024‑25
• DHSC to propose reforms by autumn 2024
• Lawyer fees exceed patient payouts on low‑value claims
• Review examines ADR, fixed fees, and double recovery
• Government rejects publishing full review and tracking costs

Pulse Analysis

The surge in NHS clinical negligence payouts reflects broader pressures on public‑sector finances. While the NHS has long been a cornerstone of British health policy, the liability burden now rivals the cost of nuclear decommissioning, forcing ministers to confront a fiscal dilemma. By converting the £3.6 bn (≈$4.5 bn) spend into a policy priority, the DHSC signals that legal reform is as critical as clinical innovation. This shift also underscores the need for transparent data, as current reporting gaps hinder accurate cost forecasting and impede targeted interventions.

David Lock KC’s mandate focuses on three levers: expanding alternative dispute resolution (ADR), instituting fixed recoverable costs, and eliminating "double recovery" where state‑funded treatment is reimbursed twice. ADR models from Canada and Australia have shown promise in reducing litigation timelines and legal fees, but the DHSC cautions that the English legal framework and NHS structure differ markedly. Fixed recoverable costs could cap attorney fees, addressing the stark imbalance where lawyer payments on low‑value claims exceed patient compensation by more than ten‑fold—£184 m (≈$230 m) versus £70 m (≈$88 m) respectively.

The department’s refusal to publish the full review or to develop a tracking system for avoidable‑harm costs raises questions about accountability. Critics argue that without public scrutiny, reforms may lack the rigor needed to achieve sustainable savings. Nonetheless, the autumn proposal will likely outline incremental steps, balancing rapid cost containment with the need to preserve claimants’ rights. For investors and policymakers, the outcome will be a bellwether for how large public health systems manage legal risk while maintaining public trust.